News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS NABRIVA SITEMAP Home / Nabriva Sitemap Sitemap Home About Nabriva Meet the Team Pipeline & Research Pleuromutilins Research Medical Education Grants Investigator-Initiated Research Grants For Investors Events & Presentations Press Releases Financial Performance Share Performance Shareholder Information Corporate Governance News & Publications Careers Contact Us Nabriva Response to COVID-19 Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic. Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics. Xenleta® (lefamulin) may be an alternative regimen for patients in need. Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors. Learn more at www.XENLETA.com. Again, to all the medical professionals, please be safe, take care of yourself and stay well. Best, Ted Schroeder CEO, Nabriva Therapeutics Continue to site Privacy Notice Patents Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland